malignant transformation
Enable an AI agent to recognise a proposed malignant transformation, assess the evidence for a change to malignant behaviour, and identify what further assessment or action is justified.
Bundle → Layer → Finding → Questions Filled
6 bundles · 11 layers · 16 findings · 26 questions
Transition identity Defines which biological change the malignant transformation claim refers to.
Meaning and starting state
Establishes the intended usage and the state from which transformation is proposed.
Specified transformation claim
Record the claimant's definition, the starting population, and whether malignancy was already present.
- Does transformation mean first acquisition of malignancy, a change within an existing malignancy, or an experimentally defined phenotype? definition
- Which observations establish the starting state, and which aspects are inferred or unknown? provenance
Precursor ancestry
Examines whether the proposed precursor and malignant endpoint belong to the relevant lineage.
Precursor-endpoint continuity
Record evidence for ancestry separately from anatomical proximity and shared diagnostic labels.
- What longitudinal, pathological, or molecular evidence connects the proposed precursor to the malignant population? provenance
- Could the observations instead represent an independent primary malignancy, a collision of lesions, or an initially missed malignant component? boundary
Malignant endpoint Makes the criteria for malignancy explicit in the relevant biological and investigative setting.
Clinical and pathological criteria
Captures the classification framework and observations used to identify a malignant endpoint.
Contextual malignancy threshold
Record the applicable tissue or lineage criteria, their authority, and any disagreement over the boundary.
- Which classification or diagnostic framework defines malignancy here, and which version is being used? definition
- Which observed features meet that framework, and how does it treat borderline lesions or in situ disease where relevant? boundary
Experimental endpoints
Separates assay-defined transformation from conclusions about malignancy in an organism.
Assay interpretation
Record what each assay demonstrates and the additional inference required to call its result malignant transformation.
- Which endpoints were measured, such as anchorage-independent growth, invasion, or tumour formation, and under what assay conditions? measurement
- What evidence distinguishes the result from immortalisation, altered proliferation, or epithelial-mesenchymal transition alone? boundary
Temporal and clonal course Represents when transformation could have occurred and how transformed populations relate across samples.
Observation timeline
Separates dated observations from inferred changes between them.
Bounded transition time
Record the last adequately assessed starting state and first supported malignant endpoint without inventing an exact onset.
- Which dated observations bound the proposed transition, and how comparable were their sampling and assessment methods? measurement
- Could apparent rapid transformation reflect delayed detection or inadequate earlier sampling? boundary
Population heterogeneity
Captures coexistence and evolution of populations within the lesion or experimental system.
Clonal and spatial distribution
Record where malignant features occur and whether evidence supports acquisition of a new state or expansion of a previously present population.
- Which sampled regions or cell populations show the malignant endpoint, and what fraction of the assessed material do they represent? measurement
- What evidence distinguishes newly acquired malignant properties from selection of an already malignant subclone? boundary
Mechanisms and enabling context Organises candidate causes and conditions supporting the proposed transition.
Cell-intrinsic alterations
Examines genetic, epigenetic, and cellular changes in the transforming population.
Candidate driver support
Record candidate alterations, their timing, and evidence for their contribution in the specified system.
- Which alterations precede or accompany the malignant endpoint, and how was their presence in the relevant population established? provenance
- Do perturbation or rescue experiments support a causal contribution, and within what biological context? measurement
Extrinsic influences
Examines exposures and tissue conditions proposed to promote or permit transformation.
Contextual contribution
Record implicated environmental, infectious, inflammatory, stromal, or immune conditions without assigning causation from coexistence.
- Which exposures or microenvironmental conditions are documented for this transition, with what timing and measurement? provenance
- What evidence separates a contribution to transformation from an effect of the resulting malignancy or a shared underlying cause? boundary
Evidence and decision limits Controls the strength of the transformation claim and identifies justified next assessments.
Claim adjudication
Integrates evidence quality, conflicting observations, and alternative explanations.
Supported claim strength
Record which parts of the transition are established, provisional, disputed, or unassessed.
- Which evidence establishes malignancy, which establishes ancestry, and which only supports a possible mechanism? provenance
- What contradictory findings, sampling limitations, or disagreements materially weaken the transformation claim? boundary
Discriminating next assessments
Links unresolved claims to assessments that could change their interpretation.
Uncertainty-linked actions
Identify the question each proposed assessment would resolve and the expertise needed to interpret it.
- Which next assessment could distinguish the leading explanations, and what result would change the claim status? action
- Which conclusions require pathology, haematology, oncology, or experimental-model review before they can guide further decisions? action
Evidence and external alignment What the world already says about this thing, gathered so the model can be checked against it.
Reported evidence
Findings from the breadth pass, kept separate from the structural claims.
Check these first
Recalled without web access and unsourced; every item is a lead to verify.
- Which of these check these first hold for the sense of malignant transformation this model covers, and on what evidence? provenance
Kinds and varieties
Recalled without web access and unsourced; every item is a lead to verify.
- Which of these kinds and varieties hold for the sense of malignant transformation this model covers, and on what evidence? provenance
Real-world use
Recalled without web access and unsourced; every item is a lead to verify.
- Which of these real-world use hold for the sense of malignant transformation this model covers, and on what evidence? provenance
Typical measurements
Recalled without web access and unsourced; every item is a lead to verify.
- Which of these typical measurements hold for the sense of malignant transformation this model covers, and on what evidence? provenance
Failure modes and hazards
Recalled without web access and unsourced; every item is a lead to verify.
- Which of these failure modes and hazards hold for the sense of malignant transformation this model covers, and on what evidence? provenance
Neighbouring kinds and how to tell them apart
Recalled without web access and unsourced; every item is a lead to verify.
- Which of these neighbouring kinds and how to tell them apart hold for the sense of malignant transformation this model covers, and on what evidence? provenance
Classifiers Filled
- Family
- Thing Registry
- Category
- Activities and processes
- Entry kind
- thing
- Plane
- ACT
- Domain
- ACT.ACT
What it is Filled
Malignant transformation is the process by which a previously nonmalignant cell or cell population acquires properties that enable it to form a malignant neoplasm, through genetic, epigenetic and cellular changes influenced by its tissue environment.
In scope
- The cell lineage or lesion undergoing the proposed transition and its relationship to any sampled precursor
- Context-specific definitions and operational criteria for a malignant endpoint
- Evidence supporting, contradicting, or leaving uncertain the transition
- Genetic, epigenetic, cellular, and microenvironmental changes implicated in the transition
- Timing, clonal evolution, and spatial variation relevant to transformation
- Limits on conclusions and follow-up actions warranted by available evidence
Out of scope
- Complete classification, staging, and management of the resulting cancer
- Benign growth, dysplasia, or metaplasia considered independently of a proposed malignant transition
- Metastatic dissemination and colonisation as separate processes
- General carcinogenic exposure assessment without a specified transformation relationship
- Laboratory immortalisation or epithelial-mesenchymal transition considered independently of malignancy
- Treatment selection, prescribing, and individual prognosis
Why it exists Filled
Enable an AI agent to recognise a proposed malignant transformation, assess the evidence for a change to malignant behaviour, and identify what further assessment or action is justified.
Distinguishing features Filled
- A transformation claim specifies a change from a starting state to a malignant endpoint; detecting an already malignant lesion does not by itself establish when or how that change occurred.
- The endpoint must satisfy criteria appropriate to the tissue, lineage, and setting; a mutation, rapid proliferation, or atypical appearance alone cannot serve as a universal criterion.
- A claim that a particular precursor transformed requires evidence connecting that precursor to the malignant population, rather than proximity or temporal succession alone.
- Immortalisation and epithelial-mesenchymal transition must be distinguished from malignant transformation unless additional evidence establishes the malignant endpoint.
- Transformation to a more aggressive form of an existing malignancy must be distinguished from first acquisition of malignancy, with the intended usage stated explicitly.
What robots and AI may and may not do Filled
Must not
- Tell a person that a lesion or result of theirs is or is not cancer.
- Promote unproven treatments or supplements to prevent or reverse transformation.
- Help modify cells or organisms in ways intended to cause cancer outside approved research.
Only with a human decision
- Any decision on screening, biopsy or treatment.
May
- Explain malignant transformation and the factors that drive it from reliable sources.
- Point people to their doctor or cancer services for questions about their own risk.
Moral aspects Filled
- Fear of cancer makes people vulnerable to false hope and fraud.
- Patients must hear diagnoses from clinicians who can support them.
Who is affected
- Patients
- People at genetic risk
- Researchers
Owners Filled
Steward
Nobody owns the process; clinicians answer for each patient and research ethics boards for each study.
Links to other meta-models Filled
parent
- Q2996394 - registry parent class
- Q65757353 - registry parent class
What else AI and robots need to interact with it Filled
Identity and identifiers required Filled
- Vercy registry: vr.tr.malignant-transformation
- Wikidata: Q752076 (https://www.wikidata.org/wiki/Q752076)
Direct properties not applicable Not applicable
- Transformation usage: first acquisition of malignancy | transformation of an existing malignancy | experimental malignant phenotype | unresolved
- Biological setting: human clinical specimen | animal in vivo | ex vivo tissue | cell culture | other specified setting
- Starting population: documented non-neoplastic | benign neoplastic | precursor lesion with classification specified | already malignant | unknown
- Tissue and lineage: anatomical site, cell lineage, and relevant lesion classification
- Endpoint assessment: criteria met | criteria partly met | criteria not met | indeterminate, with criteria and authority identified
- Precursor-endpoint relationship: supported common ancestry | possible relationship | evidence against relationship | unassessed, with method and limitations
- Transition interval: dated observation bounds and elapsed days, months, or years; unknown when unbounded
- Malignant population extent: fraction or percentage of assessed cells, tissue area, or sampled regions, with denominator and method
- Mechanistic support: association | temporal precedence | perturbation evidence | rescue evidence | unresolved
- Overall claim status: supported | provisional | disputed | unsupported | insufficient evidence
Plane ACT: no invented physical properties.
Recognition not applicable Not applicable
Not applicable
Malignant transformation is a biological process that cannot be reliably identified by unaided visual inspection.
Capabilities and actions required Filled
- Construct a context-specific transformation claim linking a starting population, endpoint, criteria, and evidence.
- Compare clinical, pathological, and experimental uses of the term without treating their endpoints as interchangeable.
- Build an observation timeline with explicit uncertainty about onset and precursor ancestry.
- Identify missing observations and discriminating assessments for competing explanations.
- Separate proposed mechanisms from established observations and rank their evidential support.
- Produce a reviewable account of what is supported, what remains unresolved, and which conclusions require specialist assessment.
Hazards and failure modes required Filled
- Malignant transformation can lead to destructive tissue invasion and impaired organ function.
- A resulting malignant neoplasm may spread to distant sites and cause life-threatening disease.
- Failure to recognize malignant change can delay appropriate clinical assessment.
- Incorrectly labeling benign changes as malignant can cause distress and unnecessary intervention.
Standards and interfaces required Filled
- The WHO Classification of Tumours, published by the International Agency for Research on Cancer, provides diagnostic classifications relevant to identifying the malignant neoplasm resulting from transformation.
Context of use required Filled
- Malignant transformation is discussed in cancer biology, pathology and studies of previously nonmalignant cell populations.
- The concept is used to interpret evidence that cells have acquired malignant behavior and to investigate the changes associated with that transition.
- It also provides context for assessing changes in previously characterized lesions.
Sources Filled
- Wikidata item Q752076: malignant transformation - identity and sense of the item
- Wikipedia: Malignant transformation - general description of the item
Open questions
- Does the registry intend malignant transformation to include transformation of an existing malignancy into a more aggressive form, or only first acquisition of malignancy?
- Which authoritative tissue-specific frameworks should define malignant endpoints, including their treatment of in situ and borderline lesions?
- What evidence thresholds should support a precursor-endpoint ancestry claim across different clinical and experimental settings?
- How should assay-defined transformation be represented when evidence for malignancy in the organism is absent or conflicting?
- Does an existing Vercy world model already own this transition, requiring this registry entry to link to it rather than receive a separate publication?
Machine files
Provenance
thing registry research (pass 2) · unreviewed
Built from: models/things/publications/thing-q752076/spec.json